Macrophages in Lupus Nephritis: Exploring a potential new therapeutic avenue
Lianne E. Kwant, Yosta Vegting, Michel Tsang-A-Sjoe, Arjan J. Kwakernaak, Liffert Vogt, Alexandre E. Voskuyl, Ronald van Vollenhoven, Menno P.J. de Winther, Fréderike J. Bemelman, Hans‐Joachim Anders, Marc Hilhorst
Abstract
Lupus nephritis (LN) is a serious complication of systemic lupus erythematosus (SLE) that occurs in about half of patients. LN is characterized by glomerular deposition of immune complexes, leading to subendothelial, mesangial and subepithelial electron dense deposits, triggering immune cell infiltration and glomerular as well as tubulointerstitial injury. Monocytes and macrophages are abundantly present in inflammatory lesions, both in glomeruli and the tubulointerstitium. Here we discuss how monocytes and macrophages are involved in this process and how monocytes and macrophages may represent specific therapeutic targets to control LN.